SciBase's EIS Technology Primary Endpoint in NIH Skin Barrier Study
SciBase Holding AB announced that the US National Institutes of Health (NIH) will use the company's EIS technology as a primary endpoint in a skin barrier study. The study will explore the impact of environmental exposure on the skin.
Swedish company SciBase Holding AB announced on October 15, 2026, that its Electrical Impedance Spectroscopy (EIS) technology will be featured prominently in a new skin barrier study led by the US National Institutes of Health (NIH). The study, titled THREAT (Testing Harms Related to Exposure to Allergenic Toxins), aims to investigate the effects of environmental exposure on the skin.
SciBase's Nevisense device and its EIS technology were selected as the primary endpoint for the study, a collaborative effort between NIH and the Swiss Institute of Allergy and Asthma Research (SIAF). The technology allows for the measurement of the skin's electrical properties, providing insights into its structure and function.
The research intends to deepen the understanding of how various environmental factors, such as allergens and toxins, affect the integrity of the skin's protective barrier. This knowledge could contribute to the development of novel approaches for the prevention and treatment of skin conditions.
SciBase specializes in AI-based devices for detection and prevention in dermatology. The company's technology is already utilized in several clinical applications, and this new study represents a significant expansion of its use in dermatological research.